Drug intelligence / Profile preview

diminazene diaceturate

Development stage: Unknown
Lead developer: Rosetta Lifecare
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

Roszene is a veterinary anti-protozoal medication containing diminazene diaceturate, developed and manufactured by Rosetta Lifecare. It is supplied as granules intended for the treatment of infections caused by *Trypanosoma* and *Babesia* species in livestock, pets, and poultry. The active ingredient, diminazene diaceturate, is a diamidine that exerts its therapeutic effect by binding to the minor groove of kinetoplast DNA (kDNA) in parasites, thereby inhibiting DNA replication and synthesis. It is a generic version of established veterinary anti-protozoals used primarily in tropical and subtropical regions to manage animal trypanosomiasis and babesiosis.

Brand names: Roszene
Other names: diminazene diaceturate

Targets

Mitochondrial DNA topoisomerase II

Beyond the preview

Go deeper on diminazene diaceturate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diminazene diaceturate.

Explore the full profile